Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: Observational results from the South Swedish Arthritis Treatment Group register

Rheumatology

Volumn 48, Issue 3, 2009, Pages 243-245

  Kristensen, Lars Erik ^a   Geborek, P ^a   Saxne, T ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ankylosing spondylitis; Anti TNF therapy; Biologics register; Infliximab; Psoriatic arthritis; Rheumatoid arthritis; Spondarthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SWEDEN; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61349195963     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken467     Document Type: Article

References (17)

1. Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, Rodriguez-Arboleya L, Navarro-Compan V, Toyos J. Dose escalation of anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology 2007;46:529-32.
2. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedvel FC, Kalden JR. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-1602.
3. Clair EWS, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
4. Van Vollenhoven RF, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: Experiences in the Stockholm biologics registry STURE. Scand J Rheum 2007;36:418-23.
5. Rahman MU, Strusberg I, Geusens P et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-8.
6. Durez P, Van den Bosch F, Coduy L et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: A Belgian prospective study. Rheumatology 2005;44:465-8.
7. Van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: Improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63:426-30.
8. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86.
9. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents tor the treatment of rheumatic diseases. Ann Rheum Dis 2007;66(Suppl. 3):2-22.
10. Geborek P, Cmkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
11. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
12. Clair EWS, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;46:1451-9.
13. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003;5:172-9.
14. Johansen C, Funding AT, Otkjaer K et al. Protein expression of TNF-α in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immun 2006;176:1431-8.
15. Pincus T, Sokka T. How can the risk of long-term consequences of rheumatoid arthntis be reduced? Baillieres Best Pract Res Clin Rheumatol 2001;15:139-70.
16. Wolfe F, Michaud K, DeWitt EM. Why results of clinical trials and observational studies of antitumor necrosis factor (anti-TNF) therapy differ: Methodological and interpretive issues. Ann Rheum Dis 2004;63(Suppl. II):iI13-17.
17. Pincus T, Sokka T. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004;63(Suppl. II):iI32-9.